Zydus Lifesciences, a reputed name in the Indian biotech industry, has made a strategic move, securing the rights for Agenus’ innovative cancer immunotherapy BOT/BAL in India and Sri Lanka. This partnership, which aligns perfectly with Zydus’ vision for advancing biologics and addressing high-unmet medical needs, is poised to significantly transform the oncology landscape in the region.
Agenus Inc., a clinical-stage immuno-oncology company, has been pioneering immune therapies that effectively combat cancer. Their lead programme, Botensilimab (BOT) and Balstilimab (BAL), is a next-generation immunotherapy platform designed to bolster and sustain the immune system’s response against tumour cells. Currently in advanced clinical trials, BOT/BAL has exhibited remarkable clinical activity across nine cancer types in more than 1,200 patients, including both late-stage and neoadjuvant settings.
This partnership leverages the strengths of both companies. It combines Agenus’ robust immuno-oncology pipeline and innovative research with Zydus’ stronghold as a leading player in Indian oncology. The alliance is an impressive stride in the fight against cancer in the region and underscores Zydus’ unwavering commitment to driving innovation in cancer treatment.
Zydus, with its robust clinical development and regulatory capabilities, will be responsible for the clinical development and regulatory approvals of BOT/BAL in the designated territories. The company will also pay a 5% royalty on net sales post the successful approval and commercialization of these licensed products.
This collaboration is not just about expanding Zydus’ reach in the oncology market, but also about pushing the boundaries of cancer treatment. By bringing transformative therapies to patients in India and Sri Lanka, Zydus aims to revolutionize cancer care in these markets.
In the words of Dr. Sharvil Patel, Managing Director of Zydus Lifesciences, “Our licensing partnership with Agenus aligns with Zydus’ overarching biologics vision and our aim to advance novel solutions for high-unmet need areas. We are confident that this collaboration will bring transformative therapies to patients who need them most, in India and Sri Lanka markets.”
Zydus is not just looking at the immediate implications of the BOT/BAL therapy within its initial indications. The company is also exploring the possibility of expanding its use into other high unmet need indications and earlier lines of treatment, as well as the neoadjuvant setting.
This strategic alliance between Zydus and Agenus intertwines the vision of two pioneers in their respective fields. It is a testament to the power of collaboration in bridging research and commercialization, thereby bringing life-saving therapies closer to patients. The partnership is a catalyst for change, marking a significant advancement in the fight against cancer in the region.
Read more from medicaldialogues.in
